Literature DB >> 9744401

Clinical effect of immunochemotherapy for a patient with advanced gallbladder cancer: report of a case.

K Murakami1, H Tanimura, H Yamaue, S Mizobata, K Noguchi, M Nakamori, T Shimamoto.   

Abstract

A 56-year-old woman was admitted presenting with a sensation of abdominal fullness. She was diagnosed to have advanced gallbladder cancer with carcinomatous peritonitis, as well as lymph node and liver metastases. We obtained highly purified tumor cells and tumor-infiltrating lymphocytes (TIL) from extirpated cervical lymph nodes and peritoneal effusion, and the chemosensitivity of these cells was tested with an MTT assay. Intensive chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5-FU) was then performed according to the results of the MTT assay. Thereafter, cytotoxic T-lymphocytes (CTL) were induced in mixed cultures of autologous tumor cells and peripheral blood lymphocytes, and adoptive immunotherapy was performed with TIL and CTL. The malignant ascites and metastatic lesions disappeared after the intraperitoneal administration of CDDP and the transfer of TIL and CTL, and subsequently the patient's quality of life improved. This patient could return to work; however, liver metastasis was later observed, and she died 14 months after the initial diagnosis. Combination therapy with anticancer drugs and activated killer cells was thus found to be effective in a patient with advanced gallbladder cancer.

Entities:  

Mesh:

Year:  1998        PMID: 9744401     DOI: 10.1007/s005950050253

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  19 in total

1.  Cisplatin treatment renders tumor cells more susceptible to attack by lymphokine-activated killer cells.

Authors:  H Yamaue; H Tanimura; K Noguchi; M Iwahashi; T Tsunoda; M Tani; M Tamai; T Hotta; S Mizobata; K Arii
Journal:  J Clin Lab Immunol       Date:  1991-08

2.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

3.  Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer.

Authors:  Y Aoki; K Takakuwa; S Kodama; K Tanaka; M Takahashi; A Tokunaga; T Takahashi
Journal:  Cancer Res       Date:  1991-04-01       Impact factor: 12.701

4.  Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.

Authors:  M Hosokawa; Y Sawamura; T Morikage; F Okada; Z Y Xu; K Morikawa; K Itoh; H Kobayashi
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

Authors:  S A Rosenberg; B S Packard; P M Aebersold; D Solomon; S L Topalian; S T Toy; P Simon; M T Lotze; J C Yang; C A Seipp
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

6.  The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumor-infiltrating lymphocytes from patients with malignant tumor.

Authors:  T Tsunoda; H Tanimura; H Yamaue; M Iwahashi; M Tani; M Tamai; K Arii; K Noguchi
Journal:  Biotherapy       Date:  1992

7.  Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer.

Authors:  G Falkson; J M MacIntyre; C G Moertel
Journal:  Cancer       Date:  1984-09-15       Impact factor: 6.860

8.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

9.  Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates.

Authors:  D E Henson; J Albores-Saavedra; D Corle
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

10.  Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay.

Authors:  H Yamaue; H Tanimura; K Noguchi; T Hotta; M Tani; T Tsunoda; M Iwahashi; M Tamai; S Iwakura
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

View more
  2 in total

1.  A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.

Authors:  Jae-Yong Cho; Ji-Sun Nam; Mi-Suk Park; Jeong-Sik Yu; Yong-Han Paik; Se-Joon Lee; Dong-Ki Lee; Dong-Sup Yoon
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

2.  A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.

Authors:  D C Doval; J S Sekhon; S K Gupta; J Fuloria; V K Shukla; S Gupta; B S Awasthy
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.